+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Incretin-based therapies, glucometabolic health and endovascular inflammation

Incretin-based therapies, glucometabolic health and endovascular inflammation

Current Pharmaceutical Design 20(31): 4953-4960

Incretin peptides are a group of gastrointestinal hormones that play a prominent role in the regulation of glucose metabolism. Incretin-based therapies (IBTs) have recently emerged as an important treatment option for patients with type 2 diabetes mellitus (T2DM). These pharmaceutical agents may be specially well suited for patients who are overweight or obese with primarily post-meal glucose peaks, and in whom traditional first-line oral agents have failed to maintain adequate glycemic control. There are 2 classes of IBTs: the dipeptidyl peptidase-4 (DPP-4) inhibitors and the glucagon-like peptide 1 (GLP-1) receptor agonists. The ultimate effect of both types of agents is to augment GLP-1 signaling, which results in enhanced glucose-dependent insulin secretion, inhibition of glucagon secretion and decreased appetite. This leads to improved regulation of glucose homeostasis accompanied by either no increase in body weight (with DPP-4 inhibitors) or a reduction (with GLP-1 receptor agonists). GLP-1 inhibits food intake and the increased GLP-1 response may contribute as a satiety signal. Although data regarding the effect of GLP-1 agonists and DPP-4 inhibitors on levels of peptides involved in the regulation of food intake in T2DM are few, an indirect effect of IBT on weight loss is possible (e.g. Exendin-4 induces adiponectin secretion in vitro). Results from animal models indicate reduction of food intake and body weight by GLP-1 agonists, but follow-up studies are required. A growing amount of evidence suggests that these peptides may also impact the cardiovascular system, including beneficial effects on myocardial cells, lipid profiles and blood pressure as well as reduced markers of systemic inflammation and improved endothelial dysfunction. The potential role of these agents in improving components of the metabolic syndrome and retardation of atherosclerosis needs to be fully elucidated. Although IBTs are currently recommended only for use in the early treatment of T2DM, the 'non-glycemic' actions of these drugs may have far reaching therapeutic implications. It is hoped that future studies will elucidate their potential strengths and weaknesses for use in various metabolic conditions.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 053810432

Download citation: RISBibTeXText

PMID: 24320037

Related references

Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies. Journal of Family Practice 59(9 Suppl 1): S5-S9, 2010

Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies. Journal of Family Practice 59(9 Suppl 1): S20-S27, 2010

Incretin Pharmacology A Review of the Incretin Effect and Current Incretin-Based Therapies. 2012

Incretin pharmacology: a review of the incretin effect and current incretin-based therapies. Cardiovascular & Hematological Agents in Medicinal Chemistry 10(4): 276-288, 2013

Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies. Journal of Family Practice 59(9 Suppl 1): S10-S19, 2010

Differentiating incretin-based therapies for population-based health care. American Journal of Managed Care 17(2 Suppl): S52-S58, 2011

Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors. Current Diabetes Reviews 4(2): 101-109, 2008

Incretin actions and consequences of incretin-based therapies: lessons from complementary animal models. Journal of Pathology 238(2): 345-358, 2016

Effects of Incretin-Based Therapies and SGLT2 Inhibitors on Skeletal Health. Current Osteoporosis Reports 14(6): 345-350, 2016

Incretin and incretin-based therapies. Nihon Rinsho. Japanese Journal of Clinical Medicine 68(5): 931-942, 2010

A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?. Diabetes Care 36(7): 2118-2125, 2014

A Critical Analysis of the Clinical Use of Incretin-Based Therapies Are the GLP-1 Therapies Safe? The benefits by far outweigh the potential risks. 2013

A Critical Analysis of the Clinical Use of Incretin-Based Therapies Are the GLP-1 Therapies Safe? How safe are the GLP-1-based therapies?. 2013

Managing recent-onset diabetes: choosing durable, well-tolerated therapies and understanding the role of incretin-based therapies. Journal of the American Osteopathic Association 114(5 Suppl 2): S6-13, 2015

Between Symmetry and Duality in Supersymmetric Quantum Field Theories. Physical Review Letters 120(7): 071604-071604, 2018